Validation Data Gallery
Tested Applications
| Positive FC detected in | HeLa cells |
Recommended dilution
| Application | Dilution |
|---|---|
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 3 publications below |
Product Information
65161-1-Ig targets MICA/MICB in WB, FC applications and shows reactivity with Human samples.
| Tested Reactivity | Human |
| Cited Reactivity | human |
| Host / Isotype | Mouse / IgG2a, kappa |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | Transfected C1R cells expressing MICA 相同性解析による交差性が予測される生物種 |
| Full Name | MHC class I polypeptide-related sequence A |
| Calculated molecular weight | 383 aa, 43 kDa |
| GenBank accession number | BC016929 |
| Gene Symbol | MICA |
| Gene ID (NCBI) | 100507436 |
| RRID | AB_2881478 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Purified by protein-A affinity chromatography |
| UNIPROT ID | Q29983 |
| Storage Buffer | PBS with 0.09% sodium azide. |
| Storage Conditions | Store at 2-8°C. Stable for one year after shipment. |
Background Information
Human MHC class I chain-related genes located within the HLA class I region of chromosome 6 encode MHC class I chain-related A and B (MICA and MICB) (PMID: 11429322). MICA and MICB are stress-inducible surface molecules that are not associated with β2-microglobulin and do not present peptides (PMID: 9497295). They are expressed in intestinal epithelium and many epithelial tumors (PMID: 10359807). MICA and MICB are ligands for NKG2D which is an activating receptor that is expressed on most natural killer (NK) cells, CD8 αβ T cells, and γδ T cells (PMID: 10426993; 11491531). The monoclonal antibody 6D4 recognizes MICA and MICB.
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for MICA/MICB antibody 65161-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
J Immunother BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma. | ||
Int Immunopharmacol Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway. | ||
Cancers (Basel) circRNF10 Regulates Tumorigenic Properties and Natural Killer Cell-Mediated Cytotoxicity against Breast Cancer through the miR-934/PTEN/PI3k-Akt Axis |